Generic industry boss: SPC manufacturing waiver won’t harm originators’ innovation

El sistema español podría mejorar su coste-eficiencia con un plan nacional

What Challenges Should Biosimilar Companies Expect In 2018?

2018 Outlook: Biosimilar Trends To Watch

Did The 2017 Biosimilar Industry Pave The Way For A Productive 2018?

Value-added medicines: how repurposed medicines bring value to patients and pharmacists

Pharmacovigilance, traceability and building trust in biosimilar medicines

Manufacturing cost transparency could combat pricing criticism, says expert

Medicines for Europe llama a poner en marcha políticas para evitar desabastecimientos

Europe needs change to drive added value